Related Experiment Videos
Systemic anti-inflammation by synthetic interleukin-1 blockers
1Department of Medical Pharmacology and Toxicology, College of Medicine, Texas A & M University, College Station 77843, USA. gchiou@tamu.edu
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica
|May 20, 2000
Summary
New interleukin-1 (IL-1) blockers, OB-101 and OB-186, demonstrate potent systemic anti-inflammatory effects and exceptional safety. These agents are highly effective in preclinical models, suggesting potential for treating inflammatory conditions like rheumatoid arthritis.
Area of Science:
- Pharmacology
- Immunology
- Inflammation Research
Background:
- Interleukin-1 (IL-1) plays a critical role in mediating systemic inflammatory responses.
- Developing targeted IL-1 blockers is a key strategy for managing inflammatory diseases.
Purpose of the Study:
- To evaluate the systemic anti-inflammatory efficacy of novel IL-1 blockers, OB-101 and OB-186.
- To assess the safety profile and therapeutic index of these compounds in preclinical models.
Main Methods:
- Utilized a carrageenan-induced paw edema model in animals to assess systemic anti-inflammatory activity.
- Determined the median lethal dose (LD50) and median effective dose (ED50) to calculate the therapeutic index.
Main Results:
- OB-101 and OB-186 exhibited 10-30 times greater potency than aspirin in inhibiting carrageenan-induced inflammation.
- Both compounds displayed remarkable safety, with LD50 values of at least 20 g/kg and therapeutic indices exceeding 2000.
Conclusions:
- OB-101 and OB-186 are potent systemic anti-inflammatory agents with an excellent safety margin.
- These IL-1 blockers show promise for treating systemic inflammatory conditions, including rheumatoid arthritis.